Researchers have identified three functional subtypes of these cells, which correspond to patients’ treatment response.
- Pairing risk prediction algorithms with active contact and follow-up or cognitive behavioral therapy could be implemented with positive results at acceptable costs to the health care system.
- Study results suggest that the accuracy of suicide prediction tools is sufficiently high to warrant pilot implementation.
Eric L. Ross, MD
[The results] suggest that current risk prediction models have achieved sufficient accuracy for health systems to move forward with pilot implementation projects.
Resident, Department of Psychiatry, Massachusetts General Hospital
BOSTON – There are several effective interventions to reduce the risk of suicide, the tenth-leading cause of death in the United States, but difficulties in identifying people at risk for suicide and concerns about the potentially high costs of suicide-prevention strategies have hampered their wider use.
But as researchers at Massachusetts General Hospital (MGH) demonstrate, statistical suicide risk prevention models could be implemented cost-effectively in U.S. health care systems and might help save many lives each year.
By evaluating data on the incidence of suicide and suicide attempts, the costs to society and the health care system of suicide, and the cost and effectiveness of suicide risk-reduction interventions, Eric L. Ross, MD, a resident in the Department of Psychiatry at MGH and colleagues found that several existing suicide risk prediction models are sufficiently accurate at identifying at-risk individuals to allow cost-effective implementation in clinical practice.
They report their findings in the journal JAMA Psychiatry.
“There are complex statistical models that researchers have come up with to predict who is at the highest risk of suicide or suicide attempts, and our analysis suggests that those models are now accurate enough that we could be implementing them in the real world,” says Ross.
“And if we do implement them, our analysis suggests they would be cost effective. That doesn’t suggest that it would save the health care system money, but it does mean it would be a good investment of resources in order to improve people’s quality of life and improve people’s longevity,” he adds.
Ross and colleagues created a mathematical model projecting suicide-related health economic outcomes over a lifetime for U.S. adults treated by primary care physicians. The model looked at the practicality of predicting individuals’ risk of suicide and then offering either of two possible interventions for people at high risk: active contact and follow-up, in which the patient at risk receives an initial intensive evaluation, and is contacted frequently thereafter by telephone or mail; and cognitive behavioral therapy, a form of psychotherapy in which the therapist helps the patient identify and change self-destructive or disturbing thought patterns.
Using standard health economics measures, the researchers found that both interventions could be cost-effective as long the models used to predict suicide risk were accurate enough. When they examined prediction models developed by previous researchers, they found that several of these models would be accurate enough to be practical and cost-effective.
“[The results] suggest that current risk prediction models have achieved sufficient accuracy for health systems to move forward with pilot implementation projects,” Ross and colleagues write in the paper’s conclusion.
According to senior author Jordan W. Smoller, MD, ScD, of the Department of Psychiatry at MGH, “suicide rates have increased substantially over the past 20 years, so it is clear that we need new tools for addressing this national problem. Most individuals who die by suicide are seen by health care providers in the months before their death, so health care settings have a crucial opportunity to prevent this tragedy. Our results suggest that the tools exist to enable cost-effective interventions. And that, I think, is cause for hope.”
Other co-authors are Kelly L. Zuromski, PhD, and Matthew K. Nock, PhD, of the Department of Psychology at Harvard University; Ben Y. Reis, PhD, of Boston Children’s Hospital; and Ronald C. Kessler, PhD, of the Department of Health Care Policy at Harvard Medical School.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Oct | 20 | 2021
Immune checkpoint inhibitors caused changes to immune cells in the cerebrospinal fluid of treated patients and generated promising results in a phase II clinical trial.
- Press Release
- Oct | 19 | 2021
In pregnant women with COVID-19, sex of fetus may influence maternal and placental immune response and neonatal immune protection
The placentas of male and female fetuses respond very differently when a mother is infected with SARS-CoV-2 during pregnancy. Male placentas have significantly increased immune activation, and males receive significantly fewer anti-COVID antibodies from their mothers.
- Press Release
- Oct | 15 | 2021
‘Superhuman, but never enough’: Essay details inequities experienced by Black women physicians in the United States
A long history of discrimination against Black women physicians persists and contributes to their underrepresentation in medicine, argue physician-scientist Fatima Cody Stanford and her coauthors.
- Press Release
- Oct | 14 | 2021
Increasing moderate-to-vigorous physical activity by 17 minutes per day, adding 54 minutes of walking per day, or reducing 249 minutes of sedentary time per day corresponded to a 5% higher peak oxygen uptake during exercise.
- Press Release
- Sep | 21 | 2021
Investigational drug SLS-005 (Trehalose) receives “May Proceed” notice and Central IRB approval for the HEALEY ALS Platform Trial
The Sean M. Healey & AMG Center for ALS at MGH received approval to proceed with adding SLS-005 (Trehalose) as an additional regimen in the HEALEY ALS Platform Trial.